Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases.
- Author:
Ying LIU
1
;
Ma-fei KANG
;
Mei-qing LUO
;
Cui-mei DONG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adenocarcinoma; drug therapy; pathology; Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Camptothecin; administration & dosage; analogs & derivatives; Capecitabine; Deoxycytidine; administration & dosage; analogs & derivatives; Female; Fluorouracil; administration & dosage; analogs & derivatives; Humans; Male; Middle Aged; Stomach Neoplasms; drug therapy; pathology; Treatment Outcome
- From: Journal of Southern Medical University 2010;30(11):2575-2576
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and adverse effects of weekly irinotecan combined with capecitabine as a second-line chemotherapy for treatment of advanced gastric cancer.
METHODSTwenty-one patients with advanced gastric cancer who had failed first-line therapy received irinotecan on days 1 and 8 plus capecitabine on days 1-14 for a 21-day cycle. Each patient was treated for at least two cycles and evaluated 4 weeks later for the responses.
RESULTSOf the 21 patients, none showed complete remission (CR), 5 (23.8%) showed partial remission (PR), 6 (28.6%) showed stable disease (SD) and 10 (47.6%) showed progressive disease (PD). The overall response rate was 23.8%, and 11 patients (52.4%) benefited (CR+PR+SD) from the clinical therapy, with a mean time to tumor progression of 3.61±0.97 months. The main adverse effects of this regimen included myelosuppression, nausea, vomiting and diarrhea.
CONCLUSIONThe regimen of weekly irinotecan plus capecitabine has a definite effect for treatment of advanced gastric cancer with tolerable toxicity.
